Medication & Safety
Return and Refund Policy: What to Check Before You Buy
A clear return and refund policy tells you a lot about a seller before anything goes wrong. Here is what to check before...
Mounjaro and Zepbound contain exactly the same drug. Both are tirzepatide, both are made by Eli Lilly, both are weekly injections, and both use the same dose range.
The difference is regulatory, not chemical. Understanding that saves you a lot of confusion and stops you paying more than you need to for what is, molecule for molecule, an identical product.
Why one drug has two names
Tirzepatide was first approved for type 2 diabetes and launched as Mounjaro.
Its weight loss effect turned out to be substantial enough to justify a separate application for weight management. Rather than extending the Mounjaro licence, Eli Lilly brought the same drug to market under a second brand name, Zepbound, approved specifically for obesity and overweight with a weight-related condition.
This is standard practice in this field. Novo Nordisk did precisely the same thing with semaglutide, selling it as Ozempic for diabetes and Wegovy for weight management. Liraglutide follows the pattern too, sold as Victoza and Saxenda.
The reasons are practical. Separate brands allow separate approved indications, separate prescribing information, separate pricing, and separate supply allocation so that diabetes patients are not competing with weight loss demand for the same stock.
What is identical
The molecule. Tirzepatide in Mounjaro is the same tirzepatide in Zepbound. There is no formulation difference in the active drug.
The mechanism. Both activate two receptors, GLP-1 (glucagon-like peptide-1, the gut hormone that signals fullness after eating) and GIP (glucose-dependent insulinotropic polypeptide, a second gut hormone that influences insulin release and how fat tissue stores energy). This dual action is what distinguishes tirzepatide from every GLP-1-only drug.
The dose range. Both run 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg weekly.
The escalation schedule. Both start at 2.5 mg for four weeks, then step up by 2.5 mg at intervals of at least four weeks.
The side effects. Identical, because it is the same drug.
The storage. Both refrigerated before use.
What is different
The approved use. Mounjaro is licensed for type 2 diabetes. Zepbound is licensed for chronic weight management in adults with a BMI of 30 or above, or 27 and above with a weight-related condition.
The prescribing pathway. Which one you are prescribed depends on why you are being treated, not on which works better.
The price and coverage. In markets where both are sold, they are often priced differently and covered differently by insurance. Weight management drugs are frequently excluded from coverage where diabetes drugs are not, which is the single biggest practical consequence of the two-brand system.
The trial evidence cited. Mounjaro's approval rested on the SURPASS diabetes trials. Zepbound's rested on the SURMOUNT obesity trials.
What the weight loss evidence shows
The weight data most people are looking for comes from SURMOUNT-1, published in the New England Journal of Medicine in 2022, which studied adults with obesity but without diabetes over 72 weeks.
| Dose | Mean weight reduction |
|---|---|
| 5 mg | 15.0 percent |
| 10 mg | 19.5 percent |
| 15 mg | 20.9 percent |
| Placebo | 3.1 percent |
Because the molecule is identical, these figures describe what tirzepatide does regardless of which brand name appears on the pen. A person taking Mounjaro at 15 mg is taking the same thing as a person taking Zepbound at 15 mg.
One caveat worth stating. SURMOUNT-1 studied people without diabetes. Weight loss on tirzepatide tends to be somewhat lower in people who do have type 2 diabetes, which is a consistent pattern across this whole drug class rather than anything specific to tirzepatide.
Which one applies to you
If you have type 2 diabetes, Mounjaro is the relevant product and blood sugar control is the primary treatment goal, with weight loss as a substantial secondary benefit.
If you do not have diabetes and are being treated for weight, Zepbound is the relevant product.
If you have both diabetes and obesity, this is a conversation with your prescriber. Either may be appropriate depending on which indication is being treated and how coverage works where you are.
What you should not do is try to obtain the diabetes-branded product for weight loss on the assumption it is cheaper or easier to get. Doing so takes stock intended for diabetes patients, and in an unofficial market it removes any clinical oversight from a drug that genuinely needs it.
The Pakistan situation
Neither Mounjaro nor Zepbound is registered in Pakistan. Both reach the country through import channels, both require refrigerated handling, and both are priced against the dollar.
Tirzepatide supply has been constrained globally since launch because demand exceeded manufacturing capacity. That pressure reaches unofficial markets faster and harder than regulated ones, which means price volatility and availability gaps here are worse than the global picture suggests.
The duration problem is the serious one. SURMOUNT-1 measured results at 72 weeks. Sustaining nearly eighteen months of uninterrupted weekly injections, sourced through informal import, at import prices, is not realistic for most households in Pakistan.
Counterfeit risk compounds it. Where demand outstrips legal supply, fake product follows, and tirzepatide pens cannot be authenticated by appearance.
This gap is the reason registered alternatives exist locally. The METASLIM™ sublingual programme provides GLP-1 pathway appetite support as drops held under the tongue, with a physician reviewing every order before dispatch. It is a physician-reviewed supplement rather than tirzepatide, so SURMOUNT-1 figures do not apply to it and nobody should suggest they do. Its relevance is that it is obtainable, verifiable and supervised, which an imported pen from an unverifiable source is not.
For how a structured course is actually run, see our physician-guided weight loss program. Our full guide to Zepbound covers tirzepatide in depth, and Zepbound vs Wegovy compares it against semaglutide.
The summary
There is no clinical difference between Mounjaro and Zepbound. Same molecule, same manufacturer, same doses, same mechanism, same side effects.
The difference is which condition each is licensed to treat, which determines who gets prescribed which, and how each is priced and covered.
If someone tells you one works better than the other, they are mistaken. They are the same drug.
Check today's price if you want to compare a locally registered option against imported tirzepatide.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.